Tricuspid dura mater bioprostheses: more than 20-year follow-up of 3 patients.
Replacement of the tricuspid valve is sometimes necessary. We report 3 consecutive patients with tricuspid insufficiency who underwent valve replacement with glycerol-preserved, homologous dura mater cardiac bioprostheses between 1971 and 1973. The first 2 patients are well 28 and 27 years later; the last patient was lost to follow-up after 20 years. We conclude that preservation of homologous dura mater bioprostheses in glycerol may reduce rates of thromboembolism, thrombosis, and structural dysfunction during the late postoperative period.
Puig
L B
LB
Heart Institute (InCor), University of São Paulo Medical School, Brazil. lpuig@incor.usp.br
Brandão
C M
CM
Pomerantzeff
P M
PM
Gaiotto
F A
FA
de Oliveira
S A
SA
D000293:Adolescent; D000328:Adult; D001705:Bioprosthesis; D004437:Ebstein Anomaly / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis; D006801:Humans; D008297:Male; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012214:Rheumatic Heart Disease / Q000601:surgery; D014261:Tricuspid Valve / Q000601:surgery*; D014262:Tricuspid Valve Insufficiency / Q000601:surgery*